Dokumentdetails
ID
oai:pubmedcentral.nih.gov:1091...
Thema
Case ReportAutor
Du, Zhirong Wang, Zixi Zhou, Weixun Yin, Jia Zhi, YuxiangLangue
enEditor
BioMed Central
Kategorie
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Jahr
2024
Auflistungsdatum
25.03.2024
Schlüsselwörter
report omalizumab eog hypoproteinemiaZusammenfassung
BACKGROUND: Eosinophilic gastritis (EoG) has rarely been reported in conjunction with gluten-sensitive enteropathy (GSE).
When this does occur, patients typically present with gastrointestinal symptoms.
To our knowledge, hypoproteinemia has not been reported as the primary manifestation.
Anti-IgE therapy, such as omalizumab, lowers eosinophil counts in the blood, lungs, and gut.
Its efficiency in treating active EoG remain unknown.
CASE PRESENTATION: We report a 33-month-old boy with a history of food allergy and atopic dermatitis who developed recurrent edema, hypoproteinemia, and eosinophilia at the age of 14 months.
The diagnoses of EoG and GSE were confirmed based on the clinical presentation and results of gastrointestinal biopsies and serological testing.
Although prednisone and dietary intervention were initially effective, the boy developed prednisone-related facial swelling.
After stopping prednisone, his symptoms relapsed.
Subsequent treatment with omalizumab, combined with dietary intervention, showed good efficacy and safety.
CONCLUSIONS: To our knowledge, this is the first case of concurrent EoG and GSE that presented primarily with hypoproteinemia.
We highlight the rare manifestations of these two diseases to raise clinical suspicion and prevent missed and delayed diagnoses.
The pathogenesis of EoG is heterogeneous and complex.
Omalizumab showed good efficacy, indicating that IgE-mediated processes may be involved in the pathogenesis of this patient’s diseases.
Du, Zhirong,Wang, Zixi,Zhou, Weixun,Yin, Jia,Zhi, Yuxiang, 2024, Eosinophilic gastritis and gluten-sensitive enteropathy manifested as hypoproteinemia and treated with omalizumab: a case report, BioMed Central
Configurable Safety Tuning of Language Models with Synthetic Preference Data
data preference cst dpo configurable language safety
Affective flexibility as a developmental building block of cognitive reappraisal: An fMRI study
cognitive success affective flexibility
